CRIS

Permanent URI for this communityhttps://scripta.up.edu.mx/handle/20.500.12552/1

Browse

Settings

Author: search.filters.author.Olvera‐Prado, Héctor

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19
    (2022)
    Méndez‐Flores, Silvia
    ;
    Priego‐Ranero, Ángel
    ;
    Azamar‐Llamas, Daniel
    ;
    Olvera‐Prado, Héctor
    ;
    Rivas‐Redonda, Kenia Ilian
    Dear Editor: Although dexamethasone is approved for the hyperinflammation treatment of hospitalised COVID-19 patients, non-hospitalised patients do not benefit from this therapy.1 A potential drug for treating COVID-19 patients is polymerised type I collagen (PTIC). A downregulator of pro-inflammatory cytokines, adhesion molecules (ELAM-1, VCAM-1, and ICAM-1), cyclooxygenase (Cox)-1 enzyme and the collagenases expression through the modulation of transcription of factor NF-kB.2-6 The intramuscular or subcutaneous administration of PTIC to patients with active RA (Phase II studies) improved the count of swollen joints and morning stiffness; 57% of patients achieved an ACR score of 50, and 30% had disease remission with this therapeutic combination. PTIC was safe and well-tolerated in long-term treatment, without adverse effects. © Clinical and Translational Medicine
      24  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Long‐term risk of adult overweight and obesity among achalasia patients who underwent Heller Myotomy
    (2020)
    Narváez-Chávez, Sofía
    ;
    Furuzawa-Carballeda, Janette
    ;
    Coss‐Adame, Enrique
    ;
    Valdovinos‐Díaz, Miguel A.
    ;
    Peralta‐Figueroa, José
    Background: It is unknown whether surgically treated achalasia cases regain or surpass their usual weight into obesity or overweight in the long-term post-operative period. Here, we aimed to assess the incidence of overweight/obesity (Ob/Ow) and the risk for reoccurrence up to 48 months post-laparoscopic Heller myotomy (LHM). Methods: We performed a cohort of 114 achalasia cases undergoing LHM. All patients had a confirmed diagnosis of achalasia and had no added comorbidities. We followed up the body mass index (BMI) at the immediate post-operative period, and at one-, six-, 12-, 24-, and 48 months after LHM. We measured the incidence of Ob/Ow and its reoccurrence risk with Cox regression. © © 2020 John Wiley & Sons Ltd.
    Scopus© Citations 3  45  2